These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 17934830)
41. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512 [TBL] [Abstract][Full Text] [Related]
42. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734 [TBL] [Abstract][Full Text] [Related]
43. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316 [TBL] [Abstract][Full Text] [Related]
44. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380 [TBL] [Abstract][Full Text] [Related]
45. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968 [TBL] [Abstract][Full Text] [Related]
46. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561 [TBL] [Abstract][Full Text] [Related]
47. [Pharmacogenomical aspects of gastroesophageal reflux disease]. Isaev VA Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955 [TBL] [Abstract][Full Text] [Related]
49. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Klotz U Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157 [TBL] [Abstract][Full Text] [Related]
50. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419 [TBL] [Abstract][Full Text] [Related]
51. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002 [TBL] [Abstract][Full Text] [Related]
52. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474 [TBL] [Abstract][Full Text] [Related]
53. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775 [TBL] [Abstract][Full Text] [Related]
54. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082 [TBL] [Abstract][Full Text] [Related]
55. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691 [TBL] [Abstract][Full Text] [Related]
56. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356 [TBL] [Abstract][Full Text] [Related]